Skip to content
Triangle logo TriangleGet started
← Full study record

NCT07217119 · OUTCOME

DE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM · Source last updated 2026-06-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Nanogram/ millilitre (ng/mL)
Interval / dispersion
Standard Deviation
Time frame
Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks.)

What was measured

Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.

Analysis population: PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.

Groups in this outcome

1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).

2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab

Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6

Reported measurements

C1 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab4
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.00.00Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab0.00.00Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0.00.00Not reportedNot reportedNot reported
C1 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab7
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab31985.79190.29Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab50220.010478.63Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab47283.39736.00Not reportedNot reportedNot reported
C1 D1, 2 HOURS

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab9
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab31333.38256.97Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab48970.011250.09Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab47300.012637.25Not reportedNot reportedNot reported
C1 D1, 24 HOURS

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab7
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab23342.95629.64Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab34950.09689.77Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab37700.010519.32Not reportedNot reportedNot reported
C1 D4, ANYTIME SAMPLE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab16672.56065.01Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab22250.08853.78Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab26950.06100.41Not reportedNot reportedNot reported
C1 D8, ANYTIME SAMPLE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab10
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab12197.54290.74Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab15358.07106.24Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab18690.08274.19Not reportedNot reportedNot reported
C2 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab7
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab6
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5920.02982.95Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5921.33611.93Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab10561.75024.85Not reportedNot reportedNot reported
C2 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab7
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab5
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab39028.610166.40Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab50425.013992.93Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab60320.019478.63Not reportedNot reportedNot reported
C4 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab13463.36636.79Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab14532.58186.51Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab18190.014219.43Not reportedNot reportedNot reported
C4 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab4
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab75333.337026.66Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab55975.016597.46Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab68500.021672.33Not reportedNot reportedNot reported
C6 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab14450.02474.87Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab13576.710349.14Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab15026.74452.43Not reportedNot reportedNot reported
C6 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab45150.06858.94Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab62666.716740.77Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab62450.015202.80Not reportedNot reportedNot reported
C9 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab14300.0141.42Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab23533.314117.13Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab8980.07099.35Not reportedNot reportedNot reported
C9 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab3
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab2
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab47250.09828.78Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab62100.016721.54Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab75700.06929.65Not reportedNot reportedNot reported
C12 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab1
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8165.03726.45Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab15850.020718.23Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab15000.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C12 D1, END OF INFUSION

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab2
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab1
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab43250.014354.27Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab54400.025031.58Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab53800.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
C18 D1, PRE-DOSE

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab1
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab0
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8180.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab34500.0NANot reportedNot reportedSD is not applicable as only a single participant was analyzed. Mean value presented here is the actual concentration for this single participant.
EoT (up to ~ 281 weeks)

Analysis denominator · Participants

GroupSource count
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab5
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab3
Values in Nanogram/ millilitre (ng/mL) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab11052.06119.81Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab8862.011401.80Not reportedNot reportedNot reported
2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab15643.315040.13Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.00
        value
        0.0
      2. group Id
        OG001
        spread
        0.00
        value
        0.0
      3. group Id
        OG002
        spread
        0.00
        value
        0.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        4
      2. group Id
        OG001
        value
        5
      3. group Id
        OG002
        value
        4
      units
      Participants
    title
    C1 D1, PRE-DOSE
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        9190.29
        value
        31985.7
      2. group Id
        OG001
        spread
        10478.63
        value
        50220.0
      3. group Id
        OG002
        spread
        9736.00
        value
        47283.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, END OF INFUSION
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        8256.97
        value
        31333.3
      2. group Id
        OG001
        spread
        11250.09
        value
        48970.0
      3. group Id
        OG002
        spread
        12637.25
        value
        47300.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, 2 HOURS
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        5629.64
        value
        23342.9
      2. group Id
        OG001
        spread
        9689.77
        value
        34950.0
      3. group Id
        OG002
        spread
        10519.32
        value
        37700.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D1, 24 HOURS
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        6065.01
        value
        16672.5
      2. group Id
        OG001
        spread
        8853.78
        value
        22250.0
      3. group Id
        OG002
        spread
        6100.41
        value
        26950.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D4, ANYTIME SAMPLE
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        4290.74
        value
        12197.5
      2. group Id
        OG001
        spread
        7106.24
        value
        15358.0
      3. group Id
        OG002
        spread
        8274.19
        value
        18690.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      2. group Id
        OG001
        value
        10
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C1 D8, ANYTIME SAMPLE
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        2982.95
        value
        5920.0
      2. group Id
        OG001
        spread
        3611.93
        value
        5921.3
      3. group Id
        OG002
        spread
        5024.85
        value
        10561.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        8
      3. group Id
        OG002
        value
        6
      units
      Participants
    title
    C2 D1, PRE-DOSE
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        10166.40
        value
        39028.6
      2. group Id
        OG001
        spread
        13992.93
        value
        50425.0
      3. group Id
        OG002
        spread
        19478.63
        value
        60320.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        8
      3. group Id
        OG002
        value
        5
      units
      Participants
    title
    C2 D1, END OF INFUSION
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        6636.79
        value
        13463.3
      2. group Id
        OG001
        spread
        8186.51
        value
        14532.5
      3. group Id
        OG002
        spread
        14219.43
        value
        18190.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C4 D1, PRE-DOSE
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        37026.66
        value
        75333.3
      2. group Id
        OG001
        spread
        16597.46
        value
        55975.0
      3. group Id
        OG002
        spread
        21672.33
        value
        68500.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        4
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C4 D1, END OF INFUSION
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        2474.87
        value
        14450.0
      2. group Id
        OG001
        spread
        10349.14
        value
        13576.7
      3. group Id
        OG002
        spread
        4452.43
        value
        15026.7
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        3
      units
      Participants
    title
    C6 D1, PRE-DOSE
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        6858.94
        value
        45150.0
      2. group Id
        OG001
        spread
        16740.77
        value
        62666.7
      3. group Id
        OG002
        spread
        15202.80
        value
        62450.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        2
      units
      Participants
    title
    C6 D1, END OF INFUSION
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      10
    3. group Id
      OG002
      value
      6
    units
    Participants
description
Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.
dispersion Type
Standard Deviation
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) of belantamab mafodotin intravenous (IV) infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin end of infusion (EOI), once every 3 weeks (Q3W).
    id
    OG000
    title
    1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  2. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 8 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG001
    title
    2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab
  3. description
    Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion in combination with 24 mg feladilimab IV infusion, given 1 hour after belantamab mafodotin EOI Q3W.
    id
    OG002
    title
    2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab
param Type
MEAN
population Description
PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. The "0" participants analyzed represents that data was not collected for analysis at that particular time point for the respective Arms/Groups.
reporting Status
POSTED
time Frame
Predose, EOI, 2 and 24 hours postdose on C1 D1, anytime sample at C1 D4, D8; Predose and EOI on D1 of C2, C4, C6, C9, C12; Predose on C18 D1; and at EoT (up to approximately 281 weeks.)
title
DE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody
type
SECONDARY
unit Of Measure
Nanogram/ millilitre (ng/mL)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice